Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: Comparison to antibody-secreting cell responses and other immunological markers

Firdausi Qadri, Edward T. Ryan, A. S G Faruque, Firoz Ahmed, Ashraful Islam Khan, M. Monirul Islam, Syed M. Akramuzzaman, David A. Sack, Stephen B. Calderwood

Research output: Contribution to journalArticle

Abstract

Gut-derived lymphocytes transiently migrate through the peripheral circulation before homing back to mucosal sites and can be detected using an ELISPOT-based antibody secreting cell (ASC) assay. Alternatively, transiently circulating lymphocytes may be cultured in vitro, and culture supernatants may be assayed for antigen-specific responses (antibody in lymphocyte supernatant [ALS] assay). The ALS assay has not been validated extensively in natural mucosal infection, nor has the ALS response been compared to the ASC assay and other cholera-specific immunological responses. Accordingly, we examined immune responses in 30 adult patients with acute cholera in Bangladesh, compared with 10 healthy controls, measuring ALS-immunoglobulin A (IgA), ASC-IgA, and serum and fecal IgA responses to two potent Vibrio cholerae immunogens, the nontoxic B subunit of cholera toxin (CtxB) and lipopolysaccharide (LPS) and a weaker V. cholerae immunogen, the mannose-sensitive hemagglutinin (MSHA). We found significant increases of anti-CtxB, anti-LPS, and anti-MSHA IgA in supernatants of lymphocytes cultured 7 days after onset of cholera using the ALS assay. We found that ALS and ASC responses correlated extremely well; both had comparable sensitivities as the vibriocidal responses, and both procedures were more sensitive than fecal IgA measurements. An advantage of the ALS assay for studying mucosal immune responses is the ability to freeze antibodies in supernatants for subsequent evaluation; like the ASC assay, the ALS assay can distinguish recent from remote mucosal infection, a distinction that may be difficult to make in endemic settings using other procedures.

Original languageEnglish (US)
Pages (from-to)4808-4814
Number of pages7
JournalInfection and Immunity
Volume71
Issue number8
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

Antibody-Producing Cells
Cholera
Immunoglobulin A
B-Lymphocytes
Lymphocytes
Antigens
Antibodies
Vibrio cholerae
Hemagglutinins
Mannose
Lipopolysaccharides
Enzyme-Linked Immunospot Assay
Mucosal Immunity
Bangladesh
Cholera Toxin
Infection
Antibody Formation

ASJC Scopus subject areas

  • Immunology

Cite this

Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera : Comparison to antibody-secreting cell responses and other immunological markers. / Qadri, Firdausi; Ryan, Edward T.; Faruque, A. S G; Ahmed, Firoz; Khan, Ashraful Islam; Islam, M. Monirul; Akramuzzaman, Syed M.; Sack, David A.; Calderwood, Stephen B.

In: Infection and Immunity, Vol. 71, No. 8, 01.08.2003, p. 4808-4814.

Research output: Contribution to journalArticle

Qadri, Firdausi ; Ryan, Edward T. ; Faruque, A. S G ; Ahmed, Firoz ; Khan, Ashraful Islam ; Islam, M. Monirul ; Akramuzzaman, Syed M. ; Sack, David A. ; Calderwood, Stephen B. / Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera : Comparison to antibody-secreting cell responses and other immunological markers. In: Infection and Immunity. 2003 ; Vol. 71, No. 8. pp. 4808-4814.
@article{f33ef3706db8470d98692cb37e2e401d,
title = "Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: Comparison to antibody-secreting cell responses and other immunological markers",
abstract = "Gut-derived lymphocytes transiently migrate through the peripheral circulation before homing back to mucosal sites and can be detected using an ELISPOT-based antibody secreting cell (ASC) assay. Alternatively, transiently circulating lymphocytes may be cultured in vitro, and culture supernatants may be assayed for antigen-specific responses (antibody in lymphocyte supernatant [ALS] assay). The ALS assay has not been validated extensively in natural mucosal infection, nor has the ALS response been compared to the ASC assay and other cholera-specific immunological responses. Accordingly, we examined immune responses in 30 adult patients with acute cholera in Bangladesh, compared with 10 healthy controls, measuring ALS-immunoglobulin A (IgA), ASC-IgA, and serum and fecal IgA responses to two potent Vibrio cholerae immunogens, the nontoxic B subunit of cholera toxin (CtxB) and lipopolysaccharide (LPS) and a weaker V. cholerae immunogen, the mannose-sensitive hemagglutinin (MSHA). We found significant increases of anti-CtxB, anti-LPS, and anti-MSHA IgA in supernatants of lymphocytes cultured 7 days after onset of cholera using the ALS assay. We found that ALS and ASC responses correlated extremely well; both had comparable sensitivities as the vibriocidal responses, and both procedures were more sensitive than fecal IgA measurements. An advantage of the ALS assay for studying mucosal immune responses is the ability to freeze antibodies in supernatants for subsequent evaluation; like the ASC assay, the ALS assay can distinguish recent from remote mucosal infection, a distinction that may be difficult to make in endemic settings using other procedures.",
author = "Firdausi Qadri and Ryan, {Edward T.} and Faruque, {A. S G} and Firoz Ahmed and Khan, {Ashraful Islam} and Islam, {M. Monirul} and Akramuzzaman, {Syed M.} and Sack, {David A.} and Calderwood, {Stephen B.}",
year = "2003",
month = "8",
day = "1",
doi = "10.1128/IAI.71.8.4808-4814.2003",
language = "English (US)",
volume = "71",
pages = "4808--4814",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera

T2 - Comparison to antibody-secreting cell responses and other immunological markers

AU - Qadri, Firdausi

AU - Ryan, Edward T.

AU - Faruque, A. S G

AU - Ahmed, Firoz

AU - Khan, Ashraful Islam

AU - Islam, M. Monirul

AU - Akramuzzaman, Syed M.

AU - Sack, David A.

AU - Calderwood, Stephen B.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Gut-derived lymphocytes transiently migrate through the peripheral circulation before homing back to mucosal sites and can be detected using an ELISPOT-based antibody secreting cell (ASC) assay. Alternatively, transiently circulating lymphocytes may be cultured in vitro, and culture supernatants may be assayed for antigen-specific responses (antibody in lymphocyte supernatant [ALS] assay). The ALS assay has not been validated extensively in natural mucosal infection, nor has the ALS response been compared to the ASC assay and other cholera-specific immunological responses. Accordingly, we examined immune responses in 30 adult patients with acute cholera in Bangladesh, compared with 10 healthy controls, measuring ALS-immunoglobulin A (IgA), ASC-IgA, and serum and fecal IgA responses to two potent Vibrio cholerae immunogens, the nontoxic B subunit of cholera toxin (CtxB) and lipopolysaccharide (LPS) and a weaker V. cholerae immunogen, the mannose-sensitive hemagglutinin (MSHA). We found significant increases of anti-CtxB, anti-LPS, and anti-MSHA IgA in supernatants of lymphocytes cultured 7 days after onset of cholera using the ALS assay. We found that ALS and ASC responses correlated extremely well; both had comparable sensitivities as the vibriocidal responses, and both procedures were more sensitive than fecal IgA measurements. An advantage of the ALS assay for studying mucosal immune responses is the ability to freeze antibodies in supernatants for subsequent evaluation; like the ASC assay, the ALS assay can distinguish recent from remote mucosal infection, a distinction that may be difficult to make in endemic settings using other procedures.

AB - Gut-derived lymphocytes transiently migrate through the peripheral circulation before homing back to mucosal sites and can be detected using an ELISPOT-based antibody secreting cell (ASC) assay. Alternatively, transiently circulating lymphocytes may be cultured in vitro, and culture supernatants may be assayed for antigen-specific responses (antibody in lymphocyte supernatant [ALS] assay). The ALS assay has not been validated extensively in natural mucosal infection, nor has the ALS response been compared to the ASC assay and other cholera-specific immunological responses. Accordingly, we examined immune responses in 30 adult patients with acute cholera in Bangladesh, compared with 10 healthy controls, measuring ALS-immunoglobulin A (IgA), ASC-IgA, and serum and fecal IgA responses to two potent Vibrio cholerae immunogens, the nontoxic B subunit of cholera toxin (CtxB) and lipopolysaccharide (LPS) and a weaker V. cholerae immunogen, the mannose-sensitive hemagglutinin (MSHA). We found significant increases of anti-CtxB, anti-LPS, and anti-MSHA IgA in supernatants of lymphocytes cultured 7 days after onset of cholera using the ALS assay. We found that ALS and ASC responses correlated extremely well; both had comparable sensitivities as the vibriocidal responses, and both procedures were more sensitive than fecal IgA measurements. An advantage of the ALS assay for studying mucosal immune responses is the ability to freeze antibodies in supernatants for subsequent evaluation; like the ASC assay, the ALS assay can distinguish recent from remote mucosal infection, a distinction that may be difficult to make in endemic settings using other procedures.

UR - http://www.scopus.com/inward/record.url?scp=0042745625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042745625&partnerID=8YFLogxK

U2 - 10.1128/IAI.71.8.4808-4814.2003

DO - 10.1128/IAI.71.8.4808-4814.2003

M3 - Article

C2 - 12874365

AN - SCOPUS:0042745625

VL - 71

SP - 4808

EP - 4814

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 8

ER -